Literature DB >> 26338157

Dermatologic Manifestations in End-stage Renal Disease.

Mohammad Ali Shafiee1, Fatemeh Akbarian, Kinza Khalil Memon, Mehdi Aarabi, Behrouz Boroumand.   

Abstract

End-stage renal disease (ESRD) is a rapidly growing global health problem within the past decades due to increased life expectancy, diabetes mellitus, hypertension, and vascular diseases. Since ESRD is not curable definitively, patients suffering from ESRD have a very low quality of life; therefore, symptomatic management is the cornerstone of medical treatment. Uremia affects almost all body organs, such as skin, through different mechanisms including biochemical, vascular, neurologic, immunologic, hematologic, endocrine, and electrolyte and volume balance disturbances. Some of these conditions are associated with significant morbidity, and patients with ESRD commonly present with a spectrum of dermatologic disorders. Each one has its own unique presentation and treatment approaches. In this review article, we discuss the clinical presentation, pathophysiology, and treatment of the most common skin disorders associated with ESRD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26338157

Source DB:  PubMed          Journal:  Iran J Kidney Dis        ISSN: 1735-8582            Impact factor:   0.892


  3 in total

1.  Evaluation of carotid artery elasticity in patients with uremia by echo tracking.

Authors:  Hong Liang; Dawei Wang; Guoying Che; Yanxin Su
Journal:  J Med Ultrason (2001)       Date:  2018-02-16       Impact factor: 1.314

2.  A 71-Year-Old Female with Myocardial Infarction and Long-Standing Ulcers on the Thigh.

Authors:  Eduardo De Flammineis; Patrick M Mulvaney; Stefan Kraft; Martin C Mihm; Shinjita Das; Daniela Kroshinsky
Journal:  Dermatopathology (Basel)       Date:  2017-11-16

3.  Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients.

Authors:  Yu-Huan Song; Si-Yang Wang; Jia-Hui Lang; Yue-Fei Xiao; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.